Comparative Pharmacology
Head-to-head clinical analysis: OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLMESARTAN MEDOXOMIL AMLODIPINE AND HYDROCHLOROTHIAZIDE versus TEVETEN HCT.
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors, inhibiting vasoconstriction and aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx across vascular smooth muscle and cardiac muscle, causing vasodilation. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Oral, one tablet once daily. Initial dose: olmesartan 20 mg/amlodipine 5 mg/hydrochlorothiazide 12.5 mg. Titrate based on response, max dose: olmesartan 40 mg/amlodipine 10 mg/hydrochlorothiazide 25 mg daily.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Olmesartan: terminal half-life 10-15 hours; supports once-daily dosing. Amlodipine: terminal half-life 30-50 hours; allows once-daily dosing with steady state reached after 7-8 days. Hydrochlorothiazide: terminal half-life 6-15 hours; prolonged in renal impairment.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Olmesartan: ~40% excreted in urine (10-20% unchanged, rest as metabolites), ~60% in feces via bile. Amlodipine: ~60% excreted in urine (10% unchanged), 20-25% in feces. Hydrochlorothiazide: >95% excreted unchanged in urine.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination